So how does Yescarta compare with a control population in a randomised trial?
We will never know...
It's good to see that you are beginning to refrain from quoting ORR's that have little, if any, meaning as a patient-centred outcome.
It remains to be seen how durable is the survival benefit to these patients.
Given the price of the treatments, and the way they were rushed to market, and how they were hailed as a one-time treatment that eradicates the disease, we need to see convincing long-term survival.
Just what proportion of treated patients make it to 3yrs and then 5 yrs?
Only when we know this, will we get a true measure of long-term benefit.
You were selective in what you reported from your own link.
You didn't mention that the median duration of response was 11·1 months, and the median progression-free survival was 5·9 months.
I am not impressed with duration of response. Nor am I impressed with median PFS.
So it's a mixed picture at best.
Who pays for the intensive care monitoring required after Car-T infusion?
How long is the Car-T manufacturing process?
Why did Kite stop developing their Multiple Myeloma Car-T?
News 
Market Data 
Discover 
AI
